Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25816762 | 0.92 | NLRP3 (0.36) | NLRP3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25816710 | 0.82 | NLRP3 (0.51) | NLRP3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25816756 | 0.80 | NLRP3 (0.40) | NLRP3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23925426 | 0.77 | NLRP3 (0.39) | NLRP3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23925424 | 0.77 | NLRP3 (0.39) | NLRP3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23952425 | 0.77 | KDM4E (0.42) | NLRP3SMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL23952179 | 0.77 | NLRP3 (0.39) | NLRP3TP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23925433 | 0.76 | KDM4E (0.41) | NLRP3SMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL23925434 | 0.76 | KDM4E (0.41) | NLRP3SMN1; SMN2KDM4EMEN1ALDH1A1 | |
| SCHEMBL23952358 | 0.76 | NLRP3 (0.41) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885TP53 2459/4885NPC1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.